Novo Nordisk's Liver-Fat Win Meets a Street Waiting for November Proof
Published on 10/07/2026 at 14:21 | Editorial boerse-global.de
New clinical data showing that higher-dose semaglutide can normalize liver fat in the vast majority of obese patients has given Novo Nordisk a fresh scientific talking point — but it lands in a market that is far more focused on the company's next earnings report than on its pipeline science.
Presented at the annual meeting of the European diabetes association EASD, the findings come from an exploratory analysis of the STEP-UP trial. Among a subgroup of 55 adults with obesity and elevated liver-fat levels, a pooled dose of 2.4 milligrams and 7.2 milligrams of injectable semaglutide drove liver-fat content below five percent in 88.5 percent of participants after 72 weeks. In practical terms, nine out of ten patients returned to normal liver-fat readings.
Novo Nordisk paired that disclosure with early data on CagriSema, its combination candidate, in adults with type 2 diabetes. The treatment altered how the brain responds to food signals and specifically trimmed fat surrounding abdominal organs including the liver and pancreas. Preliminary analyses also indicated that patients' bone health held steady while they lost weight — a detail the company is using to argue its drugs deliver metabolic benefits that go beyond the scale.
A 2035 Revenue Ambition Sits Alongside Near-Term Doubts
Those results dovetail with the long-range targets management laid out at its capital markets day. By 2035, the Danish drugmaker is aiming for annual revenue of more than DKK 150 billion from products in its current development pipeline, and it intends to bring more than five potential blockbuster medicines to market by 2030.
Investors, however, have greeted the 2030 financial framework with restraint. As reported by Reuters, that plan envisions only mid-single-digit revenue growth with broadly stable operating margins. Worries about pricing pressure and intensifying competition in the obesity segment have dominated sentiment of late.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The stock's performance tells the same story. Shares are down 24 percent since the start of the year, even after a modest rebound on the day the EASD data circulated, when the stock added 1.3 percent to EUR 33.55.
J.P. Morgan Sees Room for a Guidance Raise
Against that grim year-to-date backdrop, J.P. Morgan analyst Richard Vosser offered a counterpoint on Monday. Vosser kept his rating at Neutral with a price target of DKK 275, but suggested the company could post strong third-quarter results and lift its full-year guidance — a prospect that cuts against the prevailing skepticism.
For the bulls to be vindicated, a simple reaffirmation of existing targets likely won't be enough after this year's share-price losses. What matters is whether third-quarter operating profit beats expectations by a wide enough margin to make a guidance upgrade unavoidable. A report showing resilient demand and expanding margins would demonstrate that Novo Nordisk is absorbing price cuts and competitive pressure better than many had feared.
The company is also underpinning the stock through its own capital measures. On Monday it disclosed buybacks under an existing program that has authorized repurchases of up to DKK 15 billion over twelve months, effective since February 4, 2026. Such moves signal financial firepower, though demand for the core medicines will ultimately determine whether operating margins stay protected.
Denecimig Delay Adds a Regulatory Wrinkle
Confidence has also taken a hit from a regulatory snag. The US Food and Drug Administration has extended its review of Denecimig, Novo Nordisk's hemophilia A treatment, because manufacturing deficiencies at a production site need to be remedied. No new timeline has been set, and no safety or efficacy problems were identified.
Management continues to target a US launch in the first half of 2027, and the 2026 financial outlook remains untouched by the delay. Even so, the absence of a firm FDA schedule is a reminder that regulatory requirements can leave deep skid marks on planning.
The November 4 Verdict
For investors, the next clear directional signal is weeks away. Novo Nordisk will publish results for the first three quarters of the current year on November 4, 2026, at 07:30 CET. Until then, the debate over a possible upgrade to the company's targets is likely to drive the narrative.
Technically, as long as the stock's year-to-date low of EUR 30.25 holds as support, there is room for a technical recovery. Should that level give way under sustained selling, the shares risk extending their medium-term downtrend. A guidance raise would mark the logical next step if the quarterly figures confirm durable demand and rising margins — evidence that the growth story is intact and the pipeline can secure future revenue. A mere confirmation of the existing corridors, by contrast, could be read as fading momentum in a market already defined by caution, and would struggle to attract new buyers.
Ad
Novo Nordisk Stock: New Analysis - 7 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
